This pilot experiment in a simian immunodeficiency virus (SIV) chronic infection model aimed at extending our previous findings that vaccination with delipidated SIV resulted in more potent and diversified antiviral responses (1). Macaques chronically infected with SIVmac239 treated with antiretroviral therapy (ART) were vaccinated with autologous delipidated virus via consecutive lymph node targeted immunizations-1, 1 and 10 μg of virus spaced monthly. Results showed all animals had lasting viral load reduction approaching 1 log compared to set-point, and disease delay. Delipidation may enhance processing/ presentation of viral antigen eliciting potent antiviral control even at such late infection stage.
Get full access to this article
View all access options for this article.
References
1.
Kitabwalla M, Villinger F, Akeefe H, Liao Z, Mayne AE, Gargano L, Conner AP, Maltais JA, Kunas G, Hildreth JE, Ansari AA, Bellotti M. Enhancement of cell mediated immune responses using lipid depleted lentivirus as immunogen: a novel approach for inducing recognition of new viral epitopes. Vaccine23:4666–4677, 2005.
2.
Davey RT Jr, Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, Natarajan V, Lempicki RA, Adelsberger JW, Miller KD, Kovacs JA, Polis MA, Walker RE, Falloon J, Masur H, Gee D, Baseler M, Dimitrov DS, Fauci AS, Lane HC. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A96:15109–15114, 1999.
3.
Libois A, Lopez A, Garcia F, Castro P, Maleno MJ, Garcia A, Climent N, Arnedo M, Gallart T, Gatell JM, Plana M. Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of HAART in early chronic HIV type-1-infected patients. AIDS Res Hum Retroviruses22: 657–666, 2006.
4.
Bongiovanni M, Adorni F, Casana M, Tordato F, Tincati C, Cicconi P, Bini T, Monforte A. Subclinical hypothyroidism in HIV-infected subjects. J Antimicrob Chemother58:1086–1089, 2006.
5.
Bongiovanni M, Casana M, Tincati C, d’Arminio Monforte A. Treatment interruptions in HIV-infected subjects. J Antimicrob Chemother58:502–505, 2006.
6.
Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, Nzunetu G, Gabillard D, Rouet F, Sorho S, Chaix ML, Eholie S, Menan H, Sauvageot D, Bissagnene E, Salamon R, Anglaret X. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet367:1981–1989, 2006.
7.
Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature443:350–354, 2006.
8.
Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med203:2223–2227, 2006.
9.
Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adams WC, Precopio ML, Schacker T, Roederer M, Douek DC, Koup RA. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med203:2281–2292, 2006.
10.
Autran B, Carcelain G, Combadiere B, Debre P. Therapeutic vaccines for chronic infections. Science305:205–208, 2004.
11.
Levy Y, Durier C, Lascaux AS, Meiffredy V, Gahery-Segard H, Goujard C, Rouzioux C, Resch M, Guillet JG, Kazatchkine M, Delfraissy JF, Aboulker JP. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. Aids20:405–413, 2006.
12.
Lu W, Wu X, Lu Y, Guo W, Andrieu JM. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med9:27–32, 2003.
13.
Andrieu JM, Lu W. A dendritic cell-based vaccine for treating HIV infection: background and preliminary results. J Intern Med261:123–131, 2007.
14.
Ide F, Nakamura T, Tomizawa M, Kawana-Tachikawa A, Odawara T, Hosoya N, Iwamoto A. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial. J Med Virol78:711–718, 2006.
15.
Johansen P, Haffner AC, Koch F, Zepter K, Erdmann I, Maloy K, Simard JJ, Storni T, Senti G, Bot A, Wuthrich B, Kundig TM. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol35:568–574, 2005.
16.
Lehner T, Wang Y, Cranage M, Bergmeier LA, Mitchell E, Tao L, Hall G, Dennis M, Cook N, Jones I, Doyle C. Protective mucosal immunity elicited by targeted lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Dev Biol Stand92:225–235, 1998.
17.
Amara RR, Villinger F, Altman JD, Lydy SL, O’Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma HL, Grimm BD, Hulsey ML, Miller J, McClure HM, McNicholl JM, Moss B, Robinson HL. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science292:69–74, 2001.
18.
O’Neill E, Bostik V, Montefiori DC, Kraiselburd E, Villinger F. IL-12/GM-CSF coadministration in an SIV DNA prime/protein boost protocol enhances Gag-specific T cells but not virus-specific neutralizing antibodies in rhesus macaques. AIDS Res Hum Retroviruses19: 883–890, 2003.
19.
Davenport MP, Ribeiro RM, Chao DL, Perelson AS. Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus. J Virol78:11340–11351, 2004.
20.
Gupta SB, Jacobson LP, Margolick JB, Rinaldo CR, Phair JP, Jamieson BD, Mehrotra DV, Robertson MN, Straus WL. Estimating the benefit of an HIV-1 vaccine that reduces viral load set point. J Infect Dis195: 546–550, 2007.
21.
Mattapallil JJ, Douek DC, Buckler-White A, Montefiori D, Letvin NL, Nabel GJ, Roederer M. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med203: 1533–1541, 2006.
22.
Harari A, Vallelian F, Meylan PR, Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol174:1037–1045, 2005.
23.
De Rosa SC, Lu FX, Yu J, Perfetto SP, Falloon J, Moser S, Evans TG, Koup R, Miller CJ, Roederer M. Vaccination in humans generates broad T cell cytokine responses. J Immunol173:5372–5380, 2004.
